EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Champions Oncology's enterprise value is $113.99 Mil.
Champions Oncology's EBITDA for the trailing twelve months (TTM) ended in Jan. 2025 was $8.43 Mil. Therefore, Champions Oncology's EV-to-EBITDA for today is 13.53.
The historical rank and industry rank for Champions Oncology's EV-to-EBITDA or its related term are showing as below:
CSBR'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -5046.3 Med: -3.18 Max: 1213.84
Current: 13.53
During the past 13 years, the highest EV-to-EBITDA of Champions Oncology was 1213.84. The lowest was -5046.30. And the median was -3.18.
CSBR's EV-to-EBITDA is ranked worse than 55.34% of 459
companies
in the Biotechnology industry
Industry Median: 10.58
vs CSBR: 13.53
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Champions Oncology EV-to-EBITDA Historical Data
The historical data trend for Champions Oncology's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Champions Oncology's EV-to-EBITDA
For the Biotechnology subindustry, Champions Oncology's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Champions Oncology's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Champions Oncology's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Champions Oncology's EV-to-EBITDA falls into.
Champions Oncology's current Enterprise Value is $113.99 Mil.
Champions Oncology's EBITDA for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.43 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Champions Oncology (NAS:CSBR) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Champions Oncology's PE Ratio (TTM) for today is calculated as:
Champions Oncology's share price for today is $8.01.
Champions Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.440.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Champions Oncology's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CSBR has been successfully added to your 